KROS insider transaction filings
Keros Therapeutics, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-20. Screen KROS transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-20 | 4 | Newton Charles W. — Director | Sale (S): 551 @ $10.30 | EDGAR |
| 2026-08-20 | 4 | Cho Esther — Chief Legal Officer | Sale (S): 4,485 @ $10.29 | EDGAR |
| 2026-08-20 | 4 | Lerner Lorena Raquel — Chief Scientific Officer | Sale (S): 3,568 @ $10.29 | EDGAR |
| 2026-08-20 | 4 | Tanini Annita — Corp. Controller & VP, Finance | Sale (S): 1,224 @ $10.29 | EDGAR |
| 2026-08-19 | 4 | BIENAIME JEAN JACQUES — Director | Purchase (P): 1,000 @ $10.27 | EDGAR |
| 2026-07-17 | 4 | BIENAIME JEAN JACQUES — Director | Purchase (P): 1,000 @ $10.61 | EDGAR |
| 2026-07-06 | 4 | Prener Anne — Director | Grant/award (A): 13,786 @ $0 · Grant/award (A): 14,870 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | BIENAIME JEAN JACQUES — Director | Purchase (P): 1,000 @ $10.19 | EDGAR |
| 2026-06-15 | 4 | Newton Charles W. — Director | Sale (S): 550 @ $10.04 | EDGAR |
| 2026-06-08 | 4 | Knowles Julius — Director | Sale (S): 2,625 @ $10.73 | EDGAR |
| 2026-06-08 | 4 | Farzan Nima — Director | Sale (S): 2,625 @ $10.73 | EDGAR |
| 2026-06-05 | 4 | Knowles Julius — Director | Grant/award (A): 7,142 @ $0 · Grant/award (A): 7,433 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Farzan Nima — Director | Grant/award (A): 7,142 @ $0 · Grant/award (A): 7,433 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Seth Alpna — Director | Grant/award (A): 7,142 @ $0 · Grant/award (A): 7,433 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Seth Alpna — Director | Sale (S): 2,625 @ $10.72 | EDGAR |
| 2026-06-05 | 4 | GRAY MARY ANN — Director | Grant/award (A): 7,142 @ $0 · Grant/award (A): 7,433 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | BIENAIME JEAN JACQUES — Director | Grant/award (A): 7,142 @ $0 · Grant/award (A): 7,433 (derivative) @ $0 | EDGAR |
| 2026-05-19 | 4 | BIENAIME JEAN JACQUES — Director | Purchase (P): 1,000 @ $10.58 | EDGAR |
| 2026-04-17 | 4 | BIENAIME JEAN JACQUES — Director | Purchase (P): 1,000 @ $11.70 | EDGAR |
| 2026-04-06 | 4 | Seehra Jasbir — CHIEF EXECUTIVE OFFICER, Director | Option exercise (M): 55,000 @ $0.30 · Option exercise (M): 55,000 (derivative) @ $0 | EDGAR |
| 2026-03-27 | 4/A | Cho Esther — Chief Legal Officer | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2026-03-11 | 4 | Newton Charles W. — Director | Grant/award (A): 13,215 @ $0 · Grant/award (A): 14,788 (derivative) @ $0 | EDGAR |
| 2026-03-11 | 4 | BIENAIME JEAN JACQUES — Director | Purchase (P): 2,000 @ $11.21 | EDGAR |
| 2026-02-26 | 4 | Cho Esther — Chief Legal Officer | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2026-02-26 | 4 | Lerner Lorena Raquel — Chief Scientific Officer | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2026-02-26 | 4 | Seehra Jasbir — CHIEF EXECUTIVE OFFICER, Director | Grant/award (A): 217,000 (derivative) @ $0 · Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2026-02-26 | 4 | Regnante Keith — CHIEF FINANCIAL OFFICER | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | Cho Esther — SVP, General Counsel | Sale (S): 4,745 @ $16.35 | EDGAR |
| 2026-02-20 | 4 | Lerner Lorena Raquel — Chief Science Officer | Sale (S): 3,873 @ $16.35 | EDGAR |
| 2026-02-20 | 4 | Seehra Jasbir — CHIEF EXECUTIVE OFFICER, Director | Sale (S): 7,015 @ $16.17 | EDGAR |
| 2026-02-20 | 4 | Regnante Keith — CHIEF FINANCIAL OFFICER | Sale (S): 4,739 @ $16.35 | EDGAR |
| 2026-01-09 | 4 | Seehra Jasbir — CHIEF EXECUTIVE OFFICER, Director | Grant/award (A): 62,500 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | Knowles Julius — Director | Disposition to issuer (D): 191,527 @ $17.75 · Disposition to issuer (D): 130,494 @ $17.75 | EDGAR |
| 2025-12-18 | 4 | GORDON CARL L — Director | Disposition to issuer (D): 140,057 @ $17.75 · Disposition to issuer (D): 74,465 @ $17.75 | EDGAR |
| 2025-12-18 | 4 | ORBIMED ADVISORS LLC — Director OrbiMed Capital GP VII LLC — Director OrbiMed Genesis GP LLC — Director | Disposition to issuer (D): 140,057 @ $17.75 · Disposition to issuer (D): 74,465 @ $17.75 | EDGAR |
| 2025-10-17 | 4 | Pontifax Management 4 G.P. (2015) Ltd. — 10% owner Pontifax (Israel) IV, L.P. — 10% owner Pontifax (Cayman) IV L.P. — 10% owner Pontifax (China) IV L.P. — 10% owner Pontifax Late Stage Fund L.P. — 10% owner Pontifax Late Stage GP Ltd. — 10% owner Kariv Tomer — Director, 10% owner Nussbaum Ran — Director, 10% owner | Sale (S): 2,284,612 @ $17.75 · Sale (S): 1,121,045 @ $17.75 · Sale (S): 1,226,412 @ $17.75 · Sale (S): 155,262 @ $17.75 | EDGAR |
| 2025-10-15 | 4 | ADAR1 Capital Management, LLC — 10% owner ADAR1 Partners, LP — 10% owner ADAR1 Capital Management GP, LLC — 10% owner Schneeberger Daniel — 10% owner | Sale (S): 4,391,237 @ $17.75 · Sale (S): 254,669 @ $17.75 · Sale (S): 743,358 @ $17.75 | EDGAR |
| 2025-09-05 | 4 | Seehra Jasbir — CHIEF EXECUTIVE OFFICER, Director | Grant/award (A): 90,500 @ $0 | EDGAR |
| 2025-06-24 | 4 | ADAR1 Capital Management, LLC — 10% owner ADAR1 Partners, LP — 10% owner ADAR1 Capital Management GP, LLC — 10% owner Schneeberger Daniel — 10% owner | Option exercise/expiry (X): 100 @ $60 · Option exercise/expiry (X): 1,400 @ $70 · Option exercise/expiry (X): 200 @ $70 · Option exercise/expiry (X): 1 (derivative) @ $0 · Option exercise/expiry (X): 14 (derivative) @ $0 · Option exercise/expiry (X): 2 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | ADAR1 Capital Management, LLC — 10% owner ADAR1 Partners, LP — 10% owner ADAR1 Capital Management GP, LLC — 10% owner Schneeberger Daniel — 10% owner | Code (E): 300 (derivative) @ $0 · Code (E): 836 (derivative) @ $0 · Code (E): 178 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4/A | Nussbaum Ran — Director, 10% owner | Holdings only — no transactions reported | EDGAR |
| 2025-06-11 | 4/A | Kariv Tomer — Director, 10% owner | Holdings only — no transactions reported | EDGAR |
| 2025-06-06 | 4 | Knowles Julius — Director | Grant/award (A): 5,250 @ $0 · Grant/award (A): 10,500 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Seth Alpna — Director | Grant/award (A): 5,250 @ $0 · Grant/award (A): 10,500 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Farzan Nima — Director | Grant/award (A): 5,250 @ $0 · Grant/award (A): 10,500 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Nussbaum Ran — Director, 10% owner | Grant/award (A): 5,250 @ $0 · Grant/award (A): 10,500 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Kariv Tomer — Director, 10% owner | Grant/award (A): 5,250 @ $0 · Grant/award (A): 10,500 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | GORDON CARL L — Director | Grant/award (A): 5,250 @ $0 · Grant/award (A): 10,500 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | GRAY MARY ANN — Director | Grant/award (A): 5,250 @ $0 · Grant/award (A): 10,500 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | BIENAIME JEAN JACQUES — Director | Grant/award (A): 5,250 @ $0 · Grant/award (A): 10,500 (derivative) @ $0 | EDGAR |
Recent 8-K events — Keros Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-03 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-03 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-30 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-22 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-06-25 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-03 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-06-01 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-09 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-04 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=KROS returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →